AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MLAB

Archbold Brian David sold $117K of MLAB

Archbold Brian David (SVP Operations) sold 1,151 shares of MESA LABORATORIES INC /CO/ (MLAB) at $101.27 ($0.12M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Archbold Brian David
Published Jun 17, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
high confidence
Mentioned
$MLAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The disclosure adds incremental information about insider activity but does not introduce new company fundamentals (no earnings, guidance, contracts, litigation, or regulatory actions).

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article provides only one sale lot size and price; without context on total insider activity, buy/sell balance, or subsequent purchases, signal quality is limited.

Relevance 3/10Novelty 4/10Timing: Filed 2026-06-17; sale executed 2026-06-16

Background

This is an SEC Form 4 insider transaction disclosure for Mesa Laboratories (MLAB), reporting an officer’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MLABNeutralHigh confidence
Context

MLAB disclosed an insider open-market sale by SVP Operations Archbold Brian David: 1,151 shares sold at $101.2670 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine Form 4 transaction with a stated 10b5-1 plan; no new operating, financial, or regulatory facts about MLAB are provided.

Market effects

Sector

No sector read-through; this is a single-company insider transaction with no accompanying business update.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of valuation or liquidity needs; traders may still fade strength if selling accelerates.

Key entities

  • public_company
    MLAB

    Issuer of the securities involved in the insider Form 4 transaction.

  • insider
    Archbold Brian David

    SVP Operations who sold 1,151 shares in an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLAB insider trading history →

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

finance.yahoo.com
$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

finance.yahoo.com
$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

tradingview.com
$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality

SEC EDGAR 8-K